

COLON  
DISEASE ORIENTED GROUP  
AGENDA  
**OPEN SESSION**

VENUE: ROSSETTI ROOM, CHELSEA HOTEL, TORONTO

DATE SATURDAY, APRIL 30th, 2016

TIME: 07:45 – 09:15

**CHAIRS: DR. DEREK JONKER & DR. SHARLENE GILL**

---

07:45 WELCOME AND INTRODUCTION **DR. D. JONKER / DR. S. GILL**

07:50 UPDATES FROM FINAL ANALYSES

**CO.23:** A PHASE III RANDOMIZED STUDY OF BBI608 AND BEST SUPPORTIVE CARE VERSUS PLACEBO AND BEST SUPPORTIVE CARE IN PATIENTS WITH PRETREATED ADVANCED COLORECTAL CARCINOMA **DR. D. JONKER**

ACTIVE/RECENTLY CLOSED TRIALS FOR UPDATE

08:00 **IND 214:** A PHASE I/II TRIAL OF MG1MA3 WITH AND WITHOUT ADVAC/MA3 IN PATIENTS WITH ADVANCED/METASTATIC COLORECTAL OR NON SMALL CELL LUNG CANCER **DR. D. JONKER**

08:05 **CO.21 (CHALLENGE):** A PHASE III STUDY OF THE IMPACT OF A PHYSICAL ACTIVITY PROGRAM ON DISEASE-FREE SURVIVAL IN PATIENTS WITH EARLY STAGE COLON CANCER: A RANDOMIZED CONTROLLED TRIAL (CHALLENGE) **DR. K. COURNEYA & DR. C. BOOTH**

APPROVED TRIALS IN DEVELOPMENT

08:10 **CO.25 (FOCUS 4):** MOLECULARLY STRATIFIED RCT PROGRAMME FOR SELECTION OF THERAPY IN METASTATIC CRC POST INDUCTION 1ST LINE TREATMENT **DR. R. GOODWIN**

08:25 **CO.26:** A PHASE II/III TRIAL OF DURVALUMAB AND TREMELIMUMAB AND BEST SUPPORTIVE CARE VS BEST SUPPORTIVE CARE ALONE IN PATIENTS WITH ADVANCED COLORECTAL ADENOCARCINOMA REFRACTORY TO STANDARD THERAPIES **DR. E. CHEN**

08:40 **CO.27 (IROCAS):** - AN ADJUVANT TRIAL OF MFOLFIRINOX VS MFOLFOX6 IN HIGH-RISK STAGE III COLON CANCER **DR. S. GILL**

COLON  
DISEASE ORIENTED GROUP  
AGENDA  
**OPEN SESSION**

VENUE: ROSSETTI ROOM, CHELSEA HOTEL, TORONTO

DATE SATURDAY, APRIL 30th, 2016

TIME: 07:45 – 09:15

**CHAIRS: DR. DEREK JONKER & DR. SHARLENE GILL**

---

NEW CONCEPTS IN DEVELOPMENT

08:55      **DREAM:** ADJUVANT AZACITIDINE VERSUS OBSERVATION AFTER PERIOPERATIVE CHEMOTHERAPY FOR METASTATIC COLORECTAL CANCER: AN OPEN, MULTICENTRE, RANDOMIZED PHASE II TRIAL **DR. B. CHAN**

INTERGROUP TASK FORCE UPDATE

09:05      **ADJUVANT:** RANDOMIZED PHASE III STUDY OF MFOLFOX6 WITH OR WITHOUT ATEZOLIZUMAB IN THE ADJUVANT TREATMENT OF PATIENTS WITH MICROSATELLITE INSTABILITY-HIGH (MSI-H) RESECTED STAGE 3 COLON CANCER **DR. D. JONKER / DR. S. GILL**

09:15    CLOSING REMARKS